LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU=Zipfel Peter F AU=Zipfel Peter F
  2. AU="Chen, Yiman"
  3. AU="Xia, Qingbin"

Suchergebnis

Treffer 1 - 10 von insgesamt 452

Suchoptionen

  1. Buch ; Dissertation / Habilitation: Staphylococcus aureus pathogenesis

    Garcia-Moreno, Marina / Tuchscherr, Lorena / Löffler, Bettina / Zipfel, Peter F. / Ignatius, Anita

    the role of different host cell types during the passage from sepsis to chronic osteomyelitis

    2021  

    Körperschaft Friedrich-Schiller-Universität Jena
    Verfasserangabe from M. Sc. Marina Garcia Moreno
    Schlagwörter Staphylococcus aureus ; Osteomyelitis ; Osteozyt
    Schlagwörter Knochenzelle ; Knochenmarkentzündung ; Myelitis ; Knochenmark
    Sprache Englisch ; Deutsch
    Umfang 81 Seiten, Illustrationen, Diagramme, 30 Seiten
    Erscheinungsort Jena
    Erscheinungsland Deutschland
    Dokumenttyp Buch ; Dissertation / Habilitation
    Dissertation / Habilitation Dissertation, Friedrich-Schiller-Universität Jena, 2021
    Anmerkung Tag der Verteidigung: 04.05.2021
    HBZ-ID HT021003374
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Kategorien

  2. Artikel ; Online: Die Rolle des Komplementsystems bei Nierenerkrankungen – Neue Aspekte.

    Zipfel, Peter F / Zipfel, Svante / Wiech, Thorsten

    Deutsche medizinische Wochenschrift (1946)

    2023  Band 148, Heft 12, Seite(n) 774–779

    Abstract: Complement is a central part of the immune system. In the human body, complement is responsible for recognition of infectious microbes, for coordinating the adaptive immune response, controlling homeotic reactions and for the non-inflammatory removal of ... ...

    Titelübersetzung Role of Complement in Kidney Diseases - New Aspects.
    Abstract Complement is a central part of the immune system. In the human body, complement is responsible for recognition of infectious microbes, for coordinating the adaptive immune response, controlling homeotic reactions and for the non-inflammatory removal of modified self-cells and infectious microbes. Complement is also closely linked to another proteolytic cascade, the coagulation system. Defective activation and altered complement regulation drives pathology of several severe human kidney diseases.This manuscript summarizes the latest developments on the role of complement in kidney diseases, on new complement inhibitors and on recent complement targeting therapies. In particular focusing on diseases (1) atypical Hemolytic Uremic Syndrome, (2) C3 Glomerulopathy, (3) Anti Neutrophil Cytoplasmic Antibody Mediated Vasculitis, (4) IgA Nephropathy, (5) Membranous Glomerulopathy, (6) Systemic Lupus Erythematosus, (7) Transplant rejection and (8) COVID 19 Infection-Triggered Kidney Diseases. More excitement is generated in this field, as more and more complement mediated diseases can be treated. Several complement targeting compounds are approved by the EMA and FDA and an increasing number of new candidates are in late phase clinical trials. In addition, clinical guidelines are developed for Diagnosis and Therapy of complement mediated diseases, new biomarkers are evaluated in clinical studies, and diagnostic guidelines are in development. The recent Covid infections showed a clear link of complement in thrombo inflammation, which ultimately results in kidney damage. These aspects have increased further the focus of complement inhibitors in COVID infections.
    Mesh-Begriff(e) Humans ; Complement Activation ; COVID-19 ; Complement System Proteins/therapeutic use ; Kidney Diseases/drug therapy ; Complement Inactivating Agents/therapeutic use ; Glomerulonephritis, IGA/drug therapy ; Glomerulonephritis, IGA/pathology ; Kidney/pathology
    Chemische Substanzen Complement System Proteins (9007-36-7) ; Complement Inactivating Agents
    Sprache Deutsch
    Erscheinungsdatum 2023-05-31
    Erscheinungsland Germany
    Dokumenttyp English Abstract ; Journal Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-1936-6697
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Buch: Complement and kidney disease

    Zipfel, Peter F.

    (Progress in inflammation research)

    2006  

    Verfasserangabe Peter F. Zipfel, ed
    Serientitel Progress in inflammation research
    Schlagwörter Kidney Diseases / etiology ; Complement System Proteins / physiology ; Hemolytic-Uremic Syndrome ; Nierenkrankheit ; Komplement
    Schlagwörter Complement ; Komplementsystem ; Nephropathie ; Nierenerkrankung ; Nierenerkrankungen ; Niere ; Renopathie
    Sprache Englisch
    Umfang XVI, 236 S. : Ill., graph. Darst., 24 cm
    Verlag Birkhäuser
    Erscheinungsort Basel u.a.
    Erscheinungsland Schweiz
    Dokumenttyp Buch
    Anmerkung Literaturangaben
    HBZ-ID HT014594635
    ISBN 978-3-7643-7166-1 ; 3-7643-7166-8
    Datenquelle Katalog ZB MED Medizin, Gesundheit

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term 'complement'.

    Zipfel, Peter F / Skerka, Christine

    Molecular immunology

    2022  Band 150, Seite(n) 90–98

    Abstract: Paul Ehrlich was a pioneering Immunobiologist and physician who coined the term 'complement' in the year 1899. He was a leading visionary scientist who worked in the late 19th and early 20th centuries in Berlin and Frankfurt. He received numerous awards ... ...

    Abstract Paul Ehrlich was a pioneering Immunobiologist and physician who coined the term 'complement' in the year 1899. He was a leading visionary scientist who worked in the late 19th and early 20th centuries in Berlin and Frankfurt. He received numerous awards and honors for his substantial contributions to immunobiology and medicine, including the identification of complement, and he received the Nobel Prize in Physiology or Medicine in 1908 in recognition of his work on immunity. During his clinical work, Paul Ehrlich treated a patient with paroxysmal hemoglobinuria and reported his diagnostic approaches, including those related to erythrocyte lysis and microscopic cell analysis, to the Verein für Innere Medicine/Society of Internal Medicine, Berlin. Paroxysmal nocturnal hemoglobinuria was shown to be a complement-mediated disease; treatment of this disease with the complement inhibitor Eculzimab/Soliris was approved by the European Medicines Agency in 2003 and by the United States Food and Drug Administration in 2007.
    Mesh-Begriff(e) Complement Inactivating Agents ; History, 20th Century ; Humans ; Male ; Nobel Prize ; Physicians ; United States
    Chemische Substanzen Complement Inactivating Agents
    Sprache Englisch
    Erscheinungsdatum 2022-08-23
    Erscheinungsland England
    Dokumenttyp Historical Article ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 424427-8
    ISSN 1872-9142 ; 0161-5890
    ISSN (online) 1872-9142
    ISSN 0161-5890
    DOI 10.1016/j.molimm.2022.08.002
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: From magic bullets to modern therapeutics: Paul Ehrlich, the German immunobiologist and physician coined the term ‘complement’

    Zipfel, Peter F. / Skerka, Christine

    Molecular immunology. 2022 Oct., v. 150

    2022  

    Abstract: Paul Ehrlich was a pioneering Immunobiologist and physician who coined the term ‘complement’ in the year 1899. He was a leading visionary scientist who worked in the late 19th and early 20th centuries in Berlin and Frankfurt. He received numerous awards ... ...

    Abstract Paul Ehrlich was a pioneering Immunobiologist and physician who coined the term ‘complement’ in the year 1899. He was a leading visionary scientist who worked in the late 19th and early 20th centuries in Berlin and Frankfurt. He received numerous awards and honors for his substantial contributions to immunobiology and medicine, including the identification of complement, and he received the Nobel Prize in Physiology or Medicine in 1908 in recognition of his work on immunity. During his clinical work, Paul Ehrlich treated a patient with paroxysmal hemoglobinuria and reported his diagnostic approaches, including those related to erythrocyte lysis and microscopic cell analysis, to the Verein für Innere Medicine/Society of Internal Medicine, Berlin. Paroxysmal nocturnal hemoglobinuria was shown to be a complement-mediated disease; treatment of this disease with the complement inhibitor Eculzimab/Soliris was approved by the European Medicines Agency in 2003 and by the United States Food and Drug Administration in 2007.
    Schlagwörter Nobel Prize ; complement ; erythrocytes ; hemoglobinuria ; immunity ; medicine ; patients ; physiology ; scientists ; therapeutics
    Sprache Englisch
    Erscheinungsverlauf 2022-10
    Umfang p. 90-98.
    Erscheinungsort Elsevier Ltd
    Dokumenttyp Artikel
    ZDB-ID 424427-8
    ISSN 1872-9142 ; 0161-5890
    ISSN (online) 1872-9142
    ISSN 0161-5890
    DOI 10.1016/j.molimm.2022.08.002
    Datenquelle NAL Katalog (AGRICOLA)

    Zusatzmaterialien

    Kategorien

  6. Artikel: Die Rolle des Komplementsystems bei Nierenerkrankungen – Neue Aspekte

    Zipfel, Peter F. / Zipfel, Svante / Wiech, Thorsten

    DMW - Deutsche Medizinische Wochenschrift

    2023  Band 148, Heft 12, Seite(n) 774–779

    Abstract: Genaue Darstellung von Komplement bei Nierenerkrankungen nachgewiesen : Eine fehlerhafte Komplementaktivierung bzw. eine defekte, unpräzise Regulation von einzelnen Reaktionen dieses Immunsystems sind in der Zwischenzeit bei mehreren unterschiedlichen ... ...

    Abstract Genaue Darstellung von Komplement bei Nierenerkrankungen nachgewiesen : Eine fehlerhafte Komplementaktivierung bzw. eine defekte, unpräzise Regulation von einzelnen Reaktionen dieses Immunsystems sind in der Zwischenzeit bei mehreren unterschiedlichen Nierenerkrankungen klar aufgezeigt worden.
    Komplementdefekte sind therapierbar : Die komplementvermittelten Pathophysiologien bei den einzelnen Erkrankungen zeigen häufig eine stetige Überaktivierung einzelner Reaktionsschritte. Das genaue Verständnis dieser Mechanismen, die oft einhergehen mit Entzündungsreaktionen, Zellrekrutierung und Zellschädigung, erlauben eine gezielte Target-Identifizierung und den Einsatz von neuen Wirkstoffen. Aktuell gibt es eine Reihe von therapeutischen Wirkstoffen, die in die Komplementkaskade eingreifen. Mehrere Wirkstoffe sind schon für den therapeutischen Einsatz zugelassen, andere befinden sich in fortgeschrittener klinischer Erprobung und sind auf dem Weg zu einer Zulassung. Bei den Wirkstoffklassen für Nierenerkrankungen handelt es sich um monoklonale Antikörper, Nanobodies, die von der variablen Domäne von einzelsträngigen Lama- oder Kameliden-Antikörpern abgeleitet sind, kleine chemische Verbindungen, RNA-basierte Moleküle, sowie rekombinante Proteine.
    Diagnostik von Komplement-Erkrankungen : Aktuell werden Leitlinien zu unterschiedlichen Aspekten der Rolle des Komplementsystems bei Nierenerkrankungen erstellt. Viele der für die Komplement-Diagnostik relevanten Untersuchungen werden häufig nur von Speziallaboren angeboten.
    Präzisierung von Biomarkern in klinischen Studien und Diagnostik-Leitfaden : Die Identifikation von selektiven krankheitsspezifischen Biomarkern ist hochrelevant. Sie sind für die präzise Diagnose und für das Monitoring nach einer (komplement-)gerichteten Therapie von größter Bedeutung.
    Komplement-Infektionen – Covid und Nierenerkrankung : Bei COVID-19-Infektionen hat sich gezeigt, dass das stark aktivierte Komplementsystem zur Thromboinflammation und Schädigung der Niere beiträgt und einen erheblichen Faktor bei dieser Infektion darstellt.
    Schlagwörter Komplement-System ; Komplement-Therapie ; Nierenerkrankungen ; Komplement-Diagnostik ; Infektions-getriggerte Komplement-Aktivierung ; complement ; treatment of complement mediated diseases ; kidney diseases ; diagnosis of complement mediated diseases ; infection-induced complement acitvation
    Sprache Deutsch
    Erscheinungsdatum 2023-05-31
    Verlag Georg Thieme Verlag KG
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-1936-6697
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: The Binding of the SARS-CoV-2 Spike Protein to Platelet Factor 4: A Proposed Mechanism for the Generation of Pathogenic Antibodies.

    Nguyen, Thi-Huong / Chen, Li-Yu / Khan, Nida Zaman / Lindenbauer, Annerose / Bui, Van-Chien / Zipfel, Peter F / Heinrich, Doris

    Biomolecules

    2024  Band 14, Heft 3

    Abstract: Pathogenic platelet factor 4 (PF4) antibodies contributed to the abnormal coagulation profiles in COVID-19 and vaccinated patients. However, the mechanism of what triggers the body to produce these antibodies has not yet been clarified. Similar patterns ... ...

    Abstract Pathogenic platelet factor 4 (PF4) antibodies contributed to the abnormal coagulation profiles in COVID-19 and vaccinated patients. However, the mechanism of what triggers the body to produce these antibodies has not yet been clarified. Similar patterns and many comparable features between the COVID-19 virus and heparin-induced thrombocytopenia (HIT) have been reported. Previously, we identified a new mechanism of autoimmunity in HIT in which PF4-antibodies self-clustered PF4 and exposed binding epitopes for other pathogenic PF4/eparin antibodies. Here, we first proved that the SARS-CoV-2 spike protein (SP) also binds to PF4. The binding was evidenced by the increase in mass and optical intensity as observed through quartz crystal microbalance and immunosorbent assay, while the switching of the surface zeta potential caused by protein interactions and binding affinity of PF4-SP were evaluated by dynamic light scattering and isothermal spectral shift analysis. Based on our results, we proposed a mechanism for the generation of PF4 antibodies in COVID-19 patients. We further validated the changes in zeta potential and interaction affinity between PF4 and SP and found that their binding mechanism differs from ACE2-SP binding. Importantly, the PF4/SP complexes facilitate the binding of anti-PF4/Heparin antibodies. Our findings offer a fresh perspective on PF4 engagement with the SARS-CoV-2 SP, illuminating the role of PF4/SP complexes in severe thrombotic events.
    Mesh-Begriff(e) Humans ; Antibodies, Monoclonal, Humanized ; COVID-19 ; Immunologic Factors ; Platelet Factor 4/chemistry ; Platelet Factor 4/metabolism ; SARS-CoV-2/metabolism ; Spike Glycoprotein, Coronavirus ; Thrombocytopenia
    Chemische Substanzen Antibodies, Monoclonal, Humanized ; Immunologic Factors ; Platelet Factor 4 (37270-94-3) ; Spike Glycoprotein, Coronavirus ; spike protein, SARS-CoV-2 ; PF4 protein, human
    Sprache Englisch
    Erscheinungsdatum 2024-02-20
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article
    ZDB-ID 2701262-1
    ISSN 2218-273X ; 2218-273X
    ISSN (online) 2218-273X
    ISSN 2218-273X
    DOI 10.3390/biom14030245
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  8. Buch ; Online ; Dissertation / Habilitation: human complement system

    Tille, Alexander [Verfasser] / Figge, Marc Thilo Günter [Gutachter] / Zipfel, Peter F. [Gutachter] / Kaderali, Lars [Gutachter]

    a mathematical analysis of its regulation

    2023  

    Verfasserangabe Alexander Tille ; Gutachter: Marc Thilo Günter Figge, Peter F. Zipfel, Lars Kaderali
    Schlagwörter Biowissenschaften, Biologie ; Life Science, Biology
    Thema/Rubrik (Code) sg570
    Sprache Englisch
    Verlag Friedrich-Schiller-Universität Jena
    Erscheinungsort Jena
    Dokumenttyp Buch ; Online ; Dissertation / Habilitation
    Datenquelle Digitale Dissertationen im Internet

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: The choline-binding proteins PspA, PspC, and LytA of

    Vilhena, Cláudia / Du, Shanshan / Battista, Miriana / Westermann, Martin / Kohler, Thomas / Hammerschmidt, Sven / Zipfel, Peter F

    Infection and immunity

    2023  Band 91, Heft 9, Seite(n) e0015423

    Abstract: Streptococcus ... ...

    Abstract Streptococcus pneumoniae
    Mesh-Begriff(e) Humans ; Streptococcus pneumoniae ; Carrier Proteins/genetics ; Carrier Proteins/metabolism ; Endothelial Cells/metabolism ; Choline/metabolism ; Bacterial Proteins/metabolism ; Pneumococcal Infections/microbiology ; Membrane Proteins/metabolism ; Erythrocytes
    Chemische Substanzen Carrier Proteins ; Choline (N91BDP6H0X) ; Bacterial Proteins ; Membrane Proteins
    Sprache Englisch
    Erscheinungsdatum 2023-08-08
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218698-6
    ISSN 1098-5522 ; 0019-9567
    ISSN (online) 1098-5522
    ISSN 0019-9567
    DOI 10.1128/iai.00154-23
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  10. Buch ; Online ; Dissertation / Habilitation: Candida albicans Tef1 bindet an Dektin-1 und Dektin-2 auf humanen Dendritischen Zellen und löst eine inflammatorische Immunantwort aus

    Reiher, Nadine [Verfasser] / Zipfel, Peter F. [Gutachter] / Slevogt, Hortense [Gutachter] / Würzner, Reinhard [Gutachter]

    2023  

    Verfasserangabe Nadine Reiher ; Gutachter: Peter F. Zipfel, Hortense Slevogt, Reinhard Würzner
    Schlagwörter Biowissenschaften, Biologie ; Life Science, Biology
    Thema/Rubrik (Code) sg570
    Sprache Deutsch
    Verlag Friedrich-Schiller-Universität Jena
    Erscheinungsort Jena
    Dokumenttyp Buch ; Online ; Dissertation / Habilitation
    Datenquelle Digitale Dissertationen im Internet

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang